Number of Americans Taking GLP-1s for Weight Loss Hits Record High: Survey
Gallup said 15% of adults have used GLP-1 drugs for weight loss, as shortages and lower prices expanded access.
- On Tuesday, the Gallup National Health and Well-Being Index reported that 11% of Americans currently use GLP-1 medications for weight loss, up from 3% in 2024, based on a survey of more than 5,000 adults.
- Falling obesity rates track with rising GLP-1 adoption, with national rates declining to 36.4% in 2026 from 39.9% in 2022, the year the Food and Drug Administration first approved Wegovy to treat weight loss.
- Despite FDA warnings against non-approved alternatives, 19% of users take compounded GLP-1s due to shortages and cost, with about one-third of these patients switching from brand-name drugs.
- Certain Medicare beneficiaries can access GLP-1 drugs for $50 under the Trump administration's temporary Bridge program, while Novo Nordisk drugs face Medicare price negotiations affecting broader accessibility.
- Past research shows a general alignment between GLP-1 usage and declining obesity rates across age groups, though effectiveness is lower for those aged 65 and older, suggesting medication access is reshaping long-term public health.
16 Articles
16 Articles
GLP-1 Drug Use Triples In Two Years As American Obesity Rate Falls, Gallup Finds
A new Gallup survey reveals that 11% of U.S. adults currently take GLP-1 medications for weight loss, a sharp rise from just 3% in 2024. The figure climbed steadily, moving from 3% in 2024 to 8% in 2025, before reaching the current 11% recorded in the latest survey conducted in mid-2026. Gallup also found that 15% of American adults report having used a GLP-1 medication for weight loss at some point, representing an increase of nine percentage p…
GLP-1 use reaches new high in US
The percentage of US citizens currently taking GLP-1 drugs such as Wegovy for weight loss has almost quadrupled to 11% from 3% in 2024. A further 4% of Americans say they’ve used the drugs in the past, Gallup polling found. Meanwhile, US obesity rates, which peaked in 2022 at 39.9%, fell further to 36.4%, suggesting, although not proving, a causal link. Early research hints at other benefits of the drugs, which were originally used for diabetes:…
Record High GLP-1 Use; Intense Interval Exercise; Endometriosis and Androgens
(MedPage Today) -- Americans' use of GLP-1 injectables for weight loss reached a record high, nearly quadrupling since 2024, according to a national Gallup poll. For patients with type 2 diabetes and peripheral artery disease, GLP-1 receptor agonists...
Number of Americans taking GLP-1s for weight loss hits record high: Survey
A record number of Americans are taking GLP-1 drugs for weight loss, according to a new Gallup survey released Tuesday — a massive increase over the past two years. According to the poll, 11 percent of Americans currently take a GLP-1 medication for weight loss, compared to just 3 percent in 2024. In addition, 15 percent…
Coverage Details
Bias Distribution
- 39% of the sources lean Left, 38% of the sources are Center
![[your]NEWS](/_next/image?url=https%3A%2F%2Fgroundnews.b-cdn.net%2Finterests%2Ffb6dc495f74049f513563c33352175eaa0ecd509.jpg%3Fwidth%3D60&w=128&q=75)
Factuality
To view factuality data please Upgrade to Premium
